Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA. The post Could buying this gene-editing penny stock at $1 make me ...

Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the Vanguard Mega Cap ETF (MGC), a passively managed exchange traded fund launched on 12/17/2007.

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

Historically, the US stock market has provided long term growth for investors. The post Betting on the US economy? Here are 3 ...

Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

The First Trust NASDAQ-100 Equal Weighted ETF (QQEW) was launched on 04/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Large Cap Growth category ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...